The Neuropharmacological Evaluation of Seaweed: A Potential Therapeutic Source.
Khoshnur JannatRengasamy BalakrishnanJun-Hyuk HanYe-Ji YuGa-Won KimDong-Kug ChoiPublished in: Cells (2023)
The most common neurodegenerative diseases (NDDs), such as Alzheimer's disease (AD) and Parkinson's disease (PD), are the seventh leading cause of mortality and morbidity in developed countries. Clinical observations of NDD patients are characterized by a progressive loss of neurons in the brain along with memory decline. The common pathological hallmarks of NDDs include oxidative stress, the dysregulation of calcium, protein aggregation, a defective protein clearance system, mitochondrial dysfunction, neuroinflammation, neuronal apoptosis, and damage to cholinergic neurons. Therefore, managing this pathology requires screening drugs with different pathological targets, and suitable drugs for slowing the progression or prevention of NDDs remain to be discovered. Among the pharmacological strategies used to manage NDDs, natural drugs represent a promising therapeutic strategy. This review discusses the neuroprotective potential of seaweed and its bioactive compounds, and safety issues, which may provide several beneficial insights that warrant further investigation.
Keyphrases
- oxidative stress
- cerebral ischemia
- end stage renal disease
- spinal cord
- chronic kidney disease
- ejection fraction
- newly diagnosed
- multiple sclerosis
- traumatic brain injury
- amino acid
- dna damage
- type diabetes
- prognostic factors
- white matter
- protein protein
- lipopolysaccharide induced
- cognitive impairment
- working memory
- drug induced
- cell death
- blood brain barrier
- induced apoptosis
- risk factors
- spinal cord injury
- binding protein
- risk assessment
- brain injury
- cardiovascular disease
- patient reported
- inflammatory response